Levofloxacina Isab (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By preventing the resealing of DNA strands, it causes lethal DNA breaks, leading to bacterial cell death. This mechanism gives it a broad spectrum of activity against many Gram‑negative and Gram‑positive organisms.

The specific dose and duration of Levofloxacina Isab are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and other clinical factors. Healthcare professionals should follow local guidelines and product labeling when selecting the appropriate regimen.

Safety data for levofloxacin in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should discuss possible exposure with their healthcare provider, as the drug may be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Levofloxacina Isab, as a fluoroquinolone, offers broad‑spectrum coverage and high oral bioavailability, though it is administered intravenously in this formulation. Compared with older fluoroquinolones, levofloxacin has enhanced activity against Gram‑positive organisms and a more favorable dosing schedule, but it shares class‑related safety considerations such as tendon toxicity and QT prolongation.

Levofloxacina Isab should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. Maintaining the cold chain preserves drug stability and potency.

Levofloxacina Isab is given by intravenous infusion. The infusion rate and duration are set by the prescribing clinician, typically over 30‑60 minutes, depending on the dose and patient tolerance. Proper aseptic technique and infusion equipment should be used to avoid contamination.

Serious adverse events include tendon rupture or tendinitis, especially in older adults or those on corticosteroids; QT interval prolongation leading to potentially fatal arrhythmias; severe hypersensitivity reactions such as Stevens‑Johnson syndrome; and central nervous system effects like seizures. Patients should be monitored closely for these signs.

Levofloxacina Isab is contraindicated in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones. It should be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, uncontrolled epilepsy, or significant QT prolongation. Caution is also advised for pregnant or lactating women and pediatric patients unless no alternative exists.